HIF-2α has a great oncogenic capacity and its overexpression correlates with poor patient outcome in colorectal carcinoma, melanoma, ovarian cancer and hepatocellular carcinoma42, 43, 44, 45, possibly also by promoting Myc activity through its binding to and stabilizing the Myc–Max heterodimer. This evidence concerns the gene EPAS1 and ovarian carcinoma.